Literature DB >> 12732623

Formation of disulfide bonds and homodimers of the major cat allergen Fel d 1 equivalent to the natural allergen by expression in Escherichia coli.

Hans Grönlund1, Tomas Bergman, Kristofer Sandström, Gunvor Alvelius, Renate Reininger, Petra Verdino, Alexander Hauswirth, Karin Liderot, Peter Valent, Susanne Spitzauer, Walter Keller, Rudolf Valenta, Marianne van Hage-Hamsten.   

Abstract

Dander from the domestic cat (Felis domesticus) is one of the most common causes of IgE-mediated allergy. Attempts to produce tetrameric folded major allergen Fel d 1 by recombinant methods with structural features similar to the natural allergen have been only partially successful. In this study, a recombinant folded Fel d 1 with molecular and biological properties similar to the natural counterpart was produced. A synthetic gene coding for direct fusion of the Fel d 1 chain 2 N-terminally to chain 1 was constructed by overlapping oligonucleotides in PCR. Escherichia coli expression resulted in a non-covalently associated homodimer with an apparent molecular mass of 30 kDa defined by size exclusion chromatography. Furthermore, each 19,177-Da subunit displayed a disulfide pattern identical to that found in the natural Fel d 1, i.e. Cys3(1) Cys73(2), Cys44(1)-Cys48(2), Cys70(1)-Cys7(2), as determined by electrospray mass spectrometry after tryptic digestion. Circular dichroism analysis showed identical folds of natural and recombinant Fel d 1. Furthermore, recombinant Fel d l reacted specifically with serum IgE, inducing expression of CD203c on basophils and lymphoproliferative responses in cat-allergic patients. The results show that the overall fold and immunological properties of the recombinant Fel d 1 are very similar to those of natural Fel d 1. Moreover, the recombinant Fel d 1 construct provides a tool for defining the three-dimensional structure of Fel d 1 and represents a reagent for diagnosis and allergen-specific immunotherapy of cat allergy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12732623     DOI: 10.1074/jbc.M301416200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  Altered immunoregulatory profile during anti-tumour necrosis factor treatment of patients with inflammatory bowel disease.

Authors:  J Grundström; L Linton; S Thunberg; H Forsslund; I Janczewska; R Befrits; M van Hage; G Gafvelin; M Eberhardson
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

2.  Fel d 1-airway inflammation prevention and treatment by co-immunization vaccine via induction of CD4+CD25-Foxp3+ Treg cells.

Authors:  Yechun Pei; Shuang Geng; Lin Liu; Fengxiang Yan; Hong Guan; Jian Hou; Yongfu Chen; Bin Wang; Xiaorong An
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

3.  Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy.

Authors:  Nicole Schmitz; Klaus Dietmeier; Monika Bauer; Melanie Maudrich; Stefan Utzinger; Simone Muntwiler; Philippe Saudan; Martin F Bachmann
Journal:  J Exp Med       Date:  2009-08-10       Impact factor: 14.307

4.  A novel adjuvant-allergen complex, CBP-rFel d 1, induces up-regulation of CD86 expression and enhances cytokine release by human dendritic cells in vitro.

Authors:  Theresa N Andersson; Gunilla J Ekman; Hans Grönlund; Eva Buentke; Tove L J Eriksson; Annika Scheynius; Marianne Van Hage-Hamsten; Guro Gafvelin
Journal:  Immunology       Date:  2004-10       Impact factor: 7.397

5.  Crystallization and preliminary crystallographic data of a Fel d 1 (1+2) construct corresponding to the major allergen from cat.

Authors:  Liselotte Kaiser; Hans Grönlund; Marianne van Hage-Hamsten; Adnane Achour
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-02-01

6.  The carbohydrate galactose-alpha-1,3-galactose is a major IgE-binding epitope on cat IgA.

Authors:  Hans Grönlund; Justus Adédoyin; Scott P Commins; Thomas A E Platts-Mills; Marianne van Hage
Journal:  J Allergy Clin Immunol       Date:  2009-04-10       Impact factor: 10.793

7.  A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS.

Authors:  Katarzyna Niespodziana; Margarete Focke-Tejkl; Birgit Linhart; Vera Civaj; Katharina Blatt; Peter Valent; Marianne van Hage; Hans Grönlund; Rudolf Valenta
Journal:  J Allergy Clin Immunol       Date:  2011-03-16       Impact factor: 10.793

8.  In vitro evolution of allergy vaccine candidates, with maintained structure, but reduced B cell and T cell activation capacity.

Authors:  Ola B Nilsson; Justus Adedoyin; Claudio Rhyner; Theresa Neimert-Andersson; Jeanette Grundström; Kurt D Berndt; Reto Crameri; Hans Grönlund
Journal:  PLoS One       Date:  2011-09-13       Impact factor: 3.240

9.  Hypoallergenic derivatives of Fel d 1 obtained by rational reassembly for allergy vaccination and tolerance induction.

Authors:  M Curin; M Weber; T Thalhamer; I Swoboda; M Focke-Tejkl; K Blatt; P Valent; K Marth; T Garmatiuk; H Grönlund; J Thalhamer; S Spitzauer; R Valenta
Journal:  Clin Exp Allergy       Date:  2014-06       Impact factor: 5.018

10.  Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression.

Authors:  John D Campbell; Karen F Buckland; Sarah J McMillan; Jennifer Kearley; William L G Oldfield; Lawrence J Stern; Hans Grönlund; Marianne van Hage; Catherine J Reynolds; Rosemary J Boyton; Stephen P Cobbold; A Barry Kay; Daniel M Altmann; Clare M Lloyd; Mark Larché
Journal:  J Exp Med       Date:  2009-06-15       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.